Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Model outcomes

3 evidence topics · 6 sources

Budget impact model of cretostimogene grenadenorepvec: model outcomes

No evidence found.

Health-state utility values used in a published cost-effectiveness model